Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Common Equity (2021 - 2024)

Opus Genetics (IRD) has disclosed Common Equity for 8 consecutive years, with $50.3 million as the latest value for Q3 2023.

  • On a quarterly basis, Common Equity rose 323.36% to $50.3 million in Q3 2023 year-over-year; TTM through Sep 2023 was $50.3 million, a 323.36% increase, with the full-year FY2022 number at $46.2 million, up 108.08% from a year prior.
  • Common Equity was $50.3 million for Q3 2023 at Opus Genetics, up from $37.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $50.3 million in Q3 2023 to a low of $9.8 million in Q1 2021.
  • A 3-year average of $26.8 million and a median of $22.2 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 42.25% in 2022, then surged 323.36% in 2023.
  • Opus Genetics' Common Equity stood at $22.2 million in 2021, then surged by 108.08% to $46.2 million in 2022, then rose by 8.74% to $50.3 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Common Equity are $50.3 million (Q3 2023), $37.7 million (Q2 2023), and $41.2 million (Q1 2023).